Literature DB >> 26329863

Synthesis and Evaluation of Novel Carbocyclic Oxetanocin A (COA-Cl) Derivatives as Potential Tube Formation Agents.

Norikazu Sakakibara1, Junsuke Igarashi, Maki Takata, Yosuke Demizu, Takashi Misawa, Masaaki Kurihara, Ryoji Konishi, Yoshihisa Kato, Tokumi Maruyama, Ikuko Tsukamoto.   

Abstract

Six novel carbocyclic oxetanocin A analogs (2-chloro-C.OXT-A; COA-Cl) with various hydroxymethylated or spiro-conjugated cyclobutane rings at the N(9)-position of the 2-chloropurine moiety were synthesized and evaluated using human umbilical vein endothelial cells. All prepared compounds (2a-f) showed good to moderate activity with angiogenic potency. Among these compounds, 100 µM cis-trans-2',3'-bis(hydroxymethyl)cyclobutyl derivative (2b), trans-3'-hydroxymethylcyclobutyl analog (2d), and 3',3'-bis(hydroxymethyl)cyclobutyl derivative (2e) had greater angiogenic activity, with relative tube areas of 3.43±0.44, 3.32±0.53, and 3.59±0.83 (mean±standard deviation (S.D.)), respectively, which was comparable to COA-Cl (3.91±0.78). These data may be important for further development of this class of compounds as potential tube formation agents.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26329863     DOI: 10.1248/cpb.c15-00386

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  2 in total

1.  COA-Cl (2-Cl-C.OXT-A) can promote coronary collateral development following acute myocardial infarction in mice.

Authors:  Toshiyuki Nishikido; Jun-Ichi Oyama; Aya Shiraki; Ikuko Tsukamoto; Junsuke Igarashi; Koichi Node
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

Review 2.  Drug/Lead Compound Hydroxymethylation as a Simple Approach to Enhance Pharmacodynamic and Pharmacokinetic Properties.

Authors:  Soraya S Santos; Rodrigo V Gonzaga; Cauê B Scarim; Jeanine Giarolla; Marina C Primi; Chung M Chin; Elizabeth I Ferreira
Journal:  Front Chem       Date:  2022-02-14       Impact factor: 5.221

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.